Wednesday, 15 January 2020

STD Testing Devices Market to Observe Strong Development by 2019

Global STD Testing Devices Market Research Report, by Type (Laboratory Devices, Point of Care (PoC) Devices), End User (Hospitals and Clinics, Diagnostics Laboratories, Research and Academic Centers, Others), Region (Americas, Europe, Asia Pacific, Middle East and Africa) - Forecast till 2025
Market Forecast
STD Testing Devices Industry accounted for USD 70.29 Billion in 2018 and is expected to register a CAGR of 9.3% during the forecast period.
Market Synopsis
Sexually transmitted disease (STDs) is an infection caused due to some organisms. STDs can be transmitted from one person to another through sexual activity and intimate contact. The cases of sexually transmitted diseases keep climbing among 45 and older Americans. 82,938 cases of gonorrhea, syphilis, and chlamydia were reported among 45 and older Americans in the year 2016.
Market Influencer
The increasing prevalence of lifestyle diseases, rising geriatric population along with increasing awareness about sex-related diseases is influencing the market growth positively. The increasing number of product launches by key players in the market are likely to act as a promising factor for the increase in the near future.  For Instance, Quest Diagnostics launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States.
Market Drivers
  • Increase in prevalence of sex-related diseases
    • Every year, 376 million new cases of chlamydia, syphilis, gonorrhea, and trichomoniasis are reported globally. The total estimated direct cost of STIs annually in the U.S. is about USD 16 billion.
    • The most common STIs affecting a lot of people are Chlamydia, gonorrhea, and syphilis. Approximately 1.5 million cases of chlamydia were reported in 2015 in US alone which represents it to be the highest number of annual cases of any condition ever reported.
    • A total of 89,239 cases of gonorrhea were reported by 27 states of the European Union in 2017.
  • Increasing prevalence of lifestyle diseases
  • Rise in healthcare expenditure
  • Increasing geriatric population
  • Increasing mergers & acquisitions by prominent players in the market
    • For instance, in 2019, the US Food and Drug Administration (FDA) has cleared two tests "The Aptima Combo 2 Assay (Hologic Inc) and the Xpert CT/NG (Cepheid)" to detect Chlamydia trachomatis and Neisseria gonorrhoeae from throat and rectum samples.
  • Increasing awareness about STIs
Market Restraints
  • Lack of information about the symptoms and causes is hampering the growth of the market.
Segmentation
By Type
  • Laboratory Devices: It is expected to hold a larger share. Laboratory devices are the traditional methods of detecting STI and a large number of hospitals and clinics are expected to be using the laboratory devices.
  • Point of Care (POC) Devices: It is expected to be the fastest-growing segment as it is less time-consuming.
By End-User
  • Hospitals and Clinics: Hospitals and clinics segment dominates the global market for The positive growth of hospitals is attributed to factors such as high volume of STD tests performed in hospital-based laboratories across the globe and growing patient population.
  • Diagnostic Laboratories: Diagnostic Laboratories segment take up the second-largest share due to the rising number of diagnostic labs and the increasing patient population.
  • Research Laboratories and Institutes: segment is projected to be the fastest-growing segment over the assessment period. The research and development activities with respect to STD diagnostics and treatment have increased in last decade which has resulted in the growing demand for the devices and kits in the R&D facilities. Besides that, government funding for the research and development for effective treatment of STD has pushed the growth of this segment. The researchers from King's College London, have published a study in Nature Communications, according to them skin vaccination can generate protective CD8 T-cells that are recruited to the genital tissues and could be used as a vaccination strategy for sexually transmitted infections (STIs).
By Region
  • Americas: It is the largest regional market owing to the factors such as large patient population, rise in prevalence of STIs, the availability of a wide variety of STD testing kits and surges in awareness about the causes of STIs and its treatments which are driving the growth of the market in this region.
    • According to the Centers for Disease Control and Prevention (CDC), more than 1300 cases of congenital syphilis, about 40% increase was reported in newborns during 2017-2018 in US. Similarly, a rise in 8487 new cases of women suffering from gonorrhea in US alone was reported during the year 2017-2018.
  • Europe: The key factors driving the market growth are the growing research and development support by government bodies for the healthcare sector, and the significant demand for STI testing is driving the growth of the STI testing devices market in Europe. Additionally, the rising initiatives by organizations are driving market growth. For Instance, EuroTEST initiative is a platform for information exchange and activities to improve early diagnosis and care of HIV, viral hepatitis, sexually transmitted infections, and tuberculosis.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global STI testing devices market. The rising patient population is driving the growth of the Asia-Pacific STI testing devices market. Additionally, increasing disposable income of the middle-class population, and improving healthcare infrastructure in emerging countries such as China and India are driving the market growth. However, unfavorable healthcare reforms may restrain the growth of the market to some extent.
  • Middle East & Africa: This region is the smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • Abbott (US)
  • MedMira Inc. (Canada)
  • Qaigen Inc. (US)
  • Thermo Fisher Scientific (US)
  • Cepheid (Danaher Corporation) (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Diasorin S.p.A (Italy)
  • Bio-Rad Laboratories, Inc. (US)
  • bioMeriuex (France)
  • Becton Dickinson and Company (US)
  • Hologic, Inc. (US)
  • GenePOC Inc. (Canada)
  • Meridian Bioscience (US)
  • OraSure Technologies (US)
Browse more Healthcare Reports @

Invisible Orthodontics Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2025

Global Invisible Orthodontics Market: By Product Type (Clear Aligners, Braces, Clear Retainers), Age Group (Below 15, 16-35, Above 35), Application (Excessive Spacing, Crowding, Malocclusion, Others), Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2025
Market Forecast
Invisible Orthodontics Market share reached a value of USD 2598.8 Million in 2018 and is expected to register a CAGR of 13.99% during the assessment period of 2019 to 2025.
Market Synopsis
With the evolving technological advancements in the dental field, the area of invisible orthodontics has gained extensive popularity. Bracket-less aligners, clear retainers, and invisible braces some of the examples of cutting-edge technologies which have been launched in recent years. The high incidence rate of dental diseases in the developing countries and the rising inclination towards the correction of teeth deformities are likely to fuel the growth of the invisible orthodontics market across the globe. For instance, in Brazil, approximately 1.4 million new orthodontic cases are reported every year. Therefore, the key players involved in the invisible orthodontics market are vigorously focusing on product approvals to expand their customer base and brace their position in the market.
Moreover, the field of dentistry is evolving day by day. Public, as well as private organizations, are focusing on catering to the changing needs of the customers in terms of providing demos, conducting campaigns and dental check-ups. Thus, the employment of such strategies will promise the growth of the invisible orthodontics substantially.
Market Influencer
Increasing support by regulatory authorities to the private and public companies, in terms of investment and product approvals, acts as a significant factor that contributes substantially to the growth of the invisible orthodontics market in the longer run.
Market Drivers
  • The increasing prevalence of dental diseases pushes the need for newer treatment options, indirectly fueling the growth of the invisible orthodontics market globally. For instance, 90% of Australians are experiencing tooth decay. Such a high occurrence rate pushes the patients to choose newer techniques and prevention methods, thus fueling the growth of the invisible orthodontics market.
  • Several established players, such as Align Technology, Inc., and Dentsply Sirona are actively involved in getting approvals from regulatory authorities for their products in the invisible orthodontics market. For instance, in March 2017, Align Technology, Inc. launched the Invisalign Teen with mandibular advancement, the first clear aligner solution for Class II correction in growing tween and teen patients. This elucidates the impression that such new approvals are sure to drive the growth of the invisible orthodontics market in the near future.
  • Partnerships and collaborations between key players and local players
  • Increasing technological improvements in the orthodontics industry
  • High investment in research and development for the development of efficient products
  • Growing awareness created by dental professionals and key players about the benefits of clear aligners among the patients
Market Restraints
  • Limitations of invisible orthodontic products. Products such as clear aligners require long treatment time, which is why some of the patients do not prefer these products. In addition, poor compliance of patients with the dentists’ instructions leads to other complications of using these aligners. This results in a decreased target audience which would be utilizing such products, indirectly curbing the growth of the market.
  • Grey market for dental distribution, in terms of illegal selling of products of low quality at a cheaper price
Segmentation
By Product Type
  • Clear Aligners: The clear aligners segment is further segmented into hard, medium, and soft. The hard aligners sub-segment held a market value of an approximate of USD 1,394 million in 2018. The clear aligners segment held the largest share in 2018 due to a number of product launches by key companies such as Align Technology, Inc., Danaher, and others.
  • Braces: This segment has been further divided into ceramic braces and lingual braces. The braces segment is expected to be the fastest-growing during the forecast period owing to the increased awareness about the benefits created by key companies by conducting campaigns and dental check-ups.
  • Clear Retainers: A clear retainer is molded perfectly to fit the new position of the teeth.
By Age Group
  • Below 15: Various companies are getting approvals of their products for adolescents. In March 2017, Align Technology, Inc. launched the Invisalign Teen clear aligner for teenagers. Such increasing initiatives by prominent players for the below 15 age group fuels the growth of this segment.
  • 16-35: People in this age group are highly affected by dental disorders, including bite issues, due to change in lifestyle in recent years. This huge patient pool acts as a perfect target audience for prominent players to develop their products. Thus, the16-35 segment is likely to be the fastest-growing segment during the forecast period.
  • Above 35: The increasing middle-aged and geriatric pool of population suffering from dental caries, weakening of gums, abnormal eruptions in the teeth, among others, are the key factors for the growth of the above 35 segment. The benefits of clear braces are becoming palpable as a growing number of adult patients are now pursuing dental care.
By Application
  • Excessive Spacing: Spacing may prevent the teeth from functioning properly and may also result in gum problems due to the lack of protection provided by the teeth. Therefore, companies are coming up with products for corrective measures and conducting workshops and campaigns to create awareness. Thus, this segment held a majority share in 2018.
  • Crowding: Crowding can either be the result of several other orthodontic problems, such as impacted teeth, and teeth that do not fall out naturally, among others.
  • Malocclusion: The market, based on malocclusion, has been segmented into open bite, deep bite, and crossbite. The malocclusion segment is expected to be the fastest-growing segment during the assessment period owing to the increasing number of patients suffering from crossbites and open bites. Moreover, companies such as Align Technology, Inc. has a portfolio of products which are primarily used for the treatment of malocclusion. Thus, such factors are fueling the growth of this segment.
  • Abnormal Eruptions: Abnormal eruption occurs when a tooth emerges through the gum in the wrong place.
  • Others: Other applications of invisible orthodontic products are for correcting overjets, underbites, and others.
By Region
  • Americas: Americas was the largest regional market in 2018, owing to the continuous activities such as acquisitions, and partnerships employed by prominent players in the major countries in America. For instance, in March 2018, Dentsply Sirona (US) announced the acquisition of OraMetrix (US), a leading industry provider of innovative 3D technology solutions in the field of orthodontics. With this, the company aims to strengthen its position in the American invisible orthodontics market.
  • Europe: The European region holds the second largest share as there is increasing support from regulatory authorities, as well as ample of distributors in the European countries. For instance, in December 2017, Institut Straumann AG (Switzerland) acquired Same Day Solutions (SDS), a dental distribution company in Portugal. This acquisition provided Straumann access to SDS’ customers, which added the sales power and has been helping in supporting the company’s operations in Portugal.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global invisible orthodontics market. Direct marketing initiatives by the manufacturers to consumers are playing a substantial role in increasing the target audience and thus increasing the market size in this region. Also, strategic joint ventures by key players are contributing to the growth of the market. For instance, in January 2019, Institut Straumann AG, a company based in Switzerland, entered into a strategic partnership with a Chinese company, Tianjin ZhengLi Technology Company Limited. With this, Institut Straumann AG obtained exclusive distribution rights in China for its clear aligners, and the company aims to leverage its strong marketing and distribution capabilities to penetrate the highly attractive Chinese market. Thus, such strategies are likely to fuel the growth of the Asia-Pacific invisible orthodontics market.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure. But, in the last few years, top companies operating in the invisible orthodontics market are involved in acquiring different local distributors in the Arabian region to gain foothold in the local markets.
Key Players
  • 3M (US)
  • Align Technology, Inc. (US)
  • Clarus Company (US)
  • ClearPath Healthcare Services (US)
  • Danaher Corporation (US)
  • Dentsply Sirona (US)
  • DynaFlex (US)
  • Henry Schein, Inc. (US)
  • Institut Straumann AG (Switzerland)
  • Ormco (US)
Browse more Healthcare Reports @

Biosimulation Market 2019 - Current and Future Plans 2025

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Biosimulation Market Trends, Research Report - Global Forecast till 2025” Gives industry size, top players and worldwide demand
According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Bio simulation Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).
Browse more Healthcare Reports @
https://www.marketresearchfuture.com/categories/healthcare-market-report

Global Physical Therapy Equipment Market Recent Trends, Growth Opportunities, Forecast by Application and Types to 2023

Market Research Future with their unique quality of simplifying the market research study, announces a deep study report on “Physical Therapy Equipment Market Research Report - Global Forecast till 2025” Gives industry size, top players and worldwide demand
Market Scenario:
The Global Physical Therapy Equipment Market Size is expected to hold a value of USD 19,100 Million by 2025 at a CAGR of 6.21%.
Market Synopsis
There has been a high level of technological improvement in physical therapy equipment in the past few years, which is fueling the global market growth. Also, as physical therapy equipment is designed specifically to assist people to either regain or improve their physical abilities; thus, number of companies are investing in this market.
Market Influencer
The increasing initiatives by public and private companies boost market growth. The growing number of equipment launches also acquisitions and mergers of key players in the market are likely to act as a promising factor for the growth in the near future.  For instance, in February 2019, Colfax acquired DJO Global, Inc. for USD 3.15 billion. This helps Colfax to widen its product portfolio in the orthopedic segment.
Market Drivers
  • Growing prevalence of orthopedic disorders
  • Rising geriatric population
  • Rising incidence of sport injuries
  • Increasing awareness about physical therapy equipment
  • Rising incidences of road accidents
  • Huge number of R&D activities in the field of physiotherapy
  • Upsurging support by public and private companies
  • Increasing mergers and acquisitions by prominent players in the market. For instance, in April 2017, Dynatronics’s acquired Hausmann Industries, a manufacturer of branded, high-quality physical therapy and athletic training products. With this acquisition, the company aimed to increase business in the physical therapy equipment market
  • Growing government schemes promoting the use of rehabilitation equipment
Market Restraints
  • Inadequate reimbursement policies for physiotherapy
  • Lack of trained and skilled personnel
Segmentation
By Product
  • Equipment: Expected to hold the largest share, owing to the wide range of applications it offers. The type of equipment is electrotherapy equipment, ultrasound equipment, exercise therapy equipment, cryotherapy equipment, combination therapy equipment, continuous passive motion (CPM) therapy equipment, shockwave therapy equipment, laser therapy equipment, traction therapy equipment, magnetic therapy equipment, and others.
  • The use of physical therapy equipment is increased due to the global increase in orthopedic diseases. For example, approximately 80% of Americans will experience back problems at some point in their lives.  Also, an estimated 10% of the world’s population suffers from lower back pain.
  • Accessories: This is expected to be the fastest segment attributed to increasing use of physical therapy equipment for the cure of musculoskeletal diseases. The accessories segment is further divided into two types, namely, physiotherapy furniture and physiotherapy tapes and bandages.
By Application
  • Musculoskeletal Applications: Expected to hold the largest share, owing to increasing incidence of musculoskeletal disorders and also increasing the geriatric population.
  • Neurological Applications: This is expected to hold the fastest segment is attributed to an increase in prevalence of neurological diseases such as paralytic attacks and strokes.
  • Cardiovascular & Pulmonary Applications: The cardiovascular and pulmonary applications segment is witnessing significant growth due to increasing prevalence of cardiovascular diseases and chronic obstructive pulmonary disease (COPD).
  • Pediatric Applications: Increased use of physical therapy for musculoskeletal (MSK) disorders in children.
  • Gynecological Applications: The role of physiotherapy is in obstetrics and gynecology involves pregnancy, labor, and the puerperium, preoperative, and postoperative periods.
  • Others: Other applications include rehabilitation centers where the use of physical therapy is increasing.
By End-User
  • Hospitals and Clinics: Hospitals and clinics are expected to hold the largest segment due to usually a large patient pool and advanced physical therapy setups in hospitals based on the need of patients. Growing awareness about new physical therapy is projected to drive the growth of this segment during the forecast period.
  • Physiotherapy Centers: Expected to hold the fastest segment, owing to growing awareness about new physical therapy among the population.
  • Home Care Settings: Many companies launching the range of physical therapy devices available for use at home.
By Region
  • Americas: The largest regional market. Countries such as the US and Canada have well-established physical therapy centers which constitute advanced physical therapy systems and instruments. This contributes to the growth of the physical therapy equipment market in this region.
  • Europe: The Europe market is expected to hold the second-largest market due to increasing prevalence of neurological disorders, orthopedic problems coupled with cardiopulmonary diseases in the region.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global physical therapy equipment market. This is due to the increasing geriatric population and a large number of patients suffering from neurological diseases in China and Japan.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • DJO Global, Inc. (US)
  • BTL Industries (US)
  • Enraf-NoniUS B.V (Europe)
  • Dynatronics Corporation (US)
  • EMS Physio (UK)
  • ITO Co. Ltd (Japan)
  • Mectronic Medicale (Europe)
  • Performance Health (Subsidiary of Madison Dearborn Partners) (US)
  • Whitehall Manufacturing (US)
  • Zimmer Medizinsysteme GmbH (Germany)
  • Colfax Corporation (US)
  • STORZ MEDICAL (US)Top of Form
Bottom of Form
Browse more Healthcare Reports @

Endovascular Aneurysm Repair Devices Market to show steady growth, 2019


Global Endovascular Aneurysm Repair Devices Research Report: By Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, and Others), by Site (Infrarenal and Pararenal), by Anatomy, and by Products (Percutaneous EVAR and Others)–Forecast Till 2023
Market Scenario
Endovascular aneurysm repair (EVAR) is a collective term for all treatments that are directed to surgically cure an aortic aneurysm located in the patient’s abdomen. Factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market.
The global endovascular aneurysm repair devices market is currently dominated by many market players. The key players in the market are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in April 2018, Vascutek Ltd. and Bolton Medical, subsidiaries of Terumo Corporation, have merged into Terumo Aortic. Combining the aortic companies into a single business, Terumo Corporation aims to grow its presence in the aortic and vascular implants market.
It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023.
Key players
·         Cardiatis SA,
·         Cardinal Health,
·         Cook Medical LLC,
·         Endologix, INC.,
·         Jotec GmbH,
·         Medtronic plc,
·         Terumo Corporation,
·         W. L. Gore & Associates, Inc.,
·         BiFlow Medical Ltd,
·         Boston Scientific Corporation,
·         Braile Biomédica,
·         Endoluminal Sciences Pty Ltd,
·         Endospan Ltd.,
·         Getinge AB,
·         Lemaitre Vascular Inc.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

Fibrocystic Breasts Diagnostics and Treatment Market, Segments, Growth and Value Chain 2019

Global Fibrocystic Breasts Diagnostics and Treatment Market: Type (Diagnosis- Mammogram and Breast Biopsy, Treatment- Medications, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptives), End-Users (Hospitals and Others)–Global Forecast Till 2023
More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Global Cardiac Monitoring and Cardiac Rhythm Management Device Market Production, Capacity, Revenue, Price, Gross Margin Analysis and forecast 2019-2023


Global Cardiac Monitoring and Cardiac Rhythm Management Device Market, by Cardiac Device (Pacemaker and Others), by Cardiac Monitoring (Electrocardiogram), by CRM (Defibrillators and Others), by End-User (Hospitals and Others)–Global Forecast Till 2023
Market Scenario
Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also to growth in the market. The global cardiac monitoring and cardiac rhythm management device market is segmented into types of cardiac devices, types of cardiac monitoring devices, types of cardiac rhythm management devices, and end-users. Further, the types of cardiac devices are segmented into pacemaker, biventricular pacemaker, implantable cardioverter defibrillator, and implantable cardiac loop recorder. Based on the types of cardiac monitoring devices the market is further segmented into electrocardiogram (ECG), Holter monitor, event monitor, implantable loop recorder, and cardiac output monitoring devices. Electrocardiogram (ECG) is further sub-segmented into telelectro-cardiogram, wireless ECG, and lead ECG test. Based on types of cardiac rhythm management devices, the market is segmented into defibrillators, pacemakers, and cardiac resynchronization therapy devices. Defibrillations are further sub-segmented into implantable defibrillators and external defibrillators. Based on end-user the market is segmented into hospitals, ambulatory surgical centers, and others.
Global cardiac monitoring and cardiac rhythm management device market is expected to grow during the forecast period (2018 to 2023) at a CAGR ~4%.
Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the cardiac monitoring and cardiac rhythm management device market. Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. The increasing demand for minimally invasive surgeries drives the growth of this market. However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market.
However, the high cost of these devices in developing nations, preference of drugs over devices in the cardiac treatment, and limited insurance coverage options are some of the factors which are hampering the growth of the market.
Key Players
Some of the key players in the global cardiac monitoring and cardiac rhythm management device market are Abiomed, Berlin Hearth, Brotionik SE and Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, General Electric(GE), Hill Rom Services Inc, Jarvik Hearth. Inc, Koninklijke Philips N.V, LivaNova plc, Medtronic plc, Nihon Kohden Corporation, ReliantHeart Inc, Schiller, and Abbott.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The cardiac monitoring and cardiac rhythm management device market in the Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European cardiac monitoring and cardiac rhythm management device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac monitoring and cardiac rhythm management device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiac monitoring device market in the Middle East and Africa has been segmented into the Middle East and Africa.
The European market is expected to be the second-largest cardiac monitoring device market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of surgeries due to the changing lifestyle is contributing to the growth of the market in this region. Asia-Pacific is expected to be the fastest-growing cardiac monitoring device market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition in the global cardiac monitoring device market by producing cost-effective products that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global cardiac monitoring device market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
In terms of market value, North America will dominate the global cardiac monitoring and cardiac rhythm management device market during the forecast period. The increasing investment by North America in cardiac devices over the last few years has led to the growth of the market in this region. Increasing number of cardiac patients, better healthcare infrastructure, and advanced technology in cardiac monitoring equipment have boosted the cardiac monitoring and cardiac rhythm management device market in North America.